Regulatory Filing :

Taiwan United States

Mechanism of Action :

Doxercalciferol is a synthetic vitamin D 2 analog that requires metabolic activation to form the active 1α,25-(OH) 2D 2 metabolite, which binds to the vitamin D receptor (VDR) to result in the selective activation of vitamin D responsive pathways. Vitamin D and doxercalciferol have been shown to reduce PTH levels by inhibiting PTH synthesis and secretion.

Indication :

Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in adult patients with Stage 3 or Stage 4 chronic kidney disease (CKD) and adult patients with CKD on dialysis.

Disclaimer
 

Please be reminded that some products listed above are still patented and can only be made available for R & D use as permitted under 35 USC ¶ 271 (e) (1); Article 69, Paragraph 1 of the Patent Act of Japan; Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004; or Article 69 (5) of the Patent Law of People’s Republic of China; or Article 60 of the Patent Act of Republic of China. We will not make, sell, offer for commercial sale or export the products listed above in/into regions or countries in which substance patents are still existing and we will not be responsible if the use of any of the above products infringes on any patent in your country.

閉じる